Information Provided By: 
Fly News Breaks for January 30, 2017
ENDP, AKRX
Jan 30, 2017 | 15:09 EDT
RBC Capital analyst Randall Stanicky said it appears that Endo's (ENDP) Par unit has received FDA approval for its version of ephedrine sulfate, adding an additional competitor to Akorn's (AKRX) largest product. He thinks this will further pressure Akorn's guidance, which he expects in late February. The analyst, who noted that his EPS view of $1.91 is "well below the Street" forecast, has a Sector Perform rating on Akorn shares.
News For AKRX;ENDP From the Last 2 Days
There are no results for your query AKRX;ENDP
